Publications

  1. Ahn DH, Uson Junior PLS, Masci P, Kosiorek H, Halfdanarson TR, Mody K, Babiker H, DeLeon T, Sonbol MB, Gores G, Smoot R, Bekaii-Saab T, Mahipal A, Mansfield A, Tran NH, Hubbard JM, Borad MJ. A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. Invest New Drugs. 2021 Aug 31 [Epub ahead of print]
    View PubMed
  2. Jin Z, Dixon JG, Fiskum JM, Parekh HD, Sinicrope FA, Yothers G, Allegra CJ, Wolmark N, Haller D, Schmoll HJ, de Gramont A, Kerr R, Taieb J, Van Cutsem E, Tweleves C, O'Connell M, Saltz LB, Sadahiro S, Blanke CD, Tomita N, Seitz JF, Erlichman C, Yoshino T, Yamanaka T, Marsoni S, Andre T, Mahipal A, Goldberg RM, George TJ, Shi Q. Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. J Natl Cancer Inst. 2021 Aug 18 [Epub ahead of print]
    View PubMed
  3. Ueberroth BE, Liu AJ, Graham RP, Bekaii-Saab TS, McWilliams RR, Mahipal A, Truty MJ, Mody K, Sonbol MB, Halfdanarson TR. Osteoclast-Like Giant Cell Tumors of the Pancreas: Clinical Characteristics, Genetic Testing, and Treatment Modalities. Pancreas. 2021 Aug 6 Epub 2021 Aug 06
    View PubMed
  4. Tran NH, Foster NR, Mahipal A, Byrne T, Hubbard J, Silva A, Mody K, Alberts S, Borad MJ. Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance). Invest New Drugs. 2021 Aug; 39 (4):1072-1080 Epub 2021 Mar 01
    View PubMed
  5. Chakrabarti S, Wintheiser G, Tella SH, Oxencis C, Mahipal A. TAS-102: A resurrected novel Fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies. Pharmacol Ther. 2021 Aug; 224:107823 Epub 2021 Mar 02
    View PubMed
  6. Kommalapati A, Tella SH, Borad M, Javle M, Mahipal A. FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice. Cancers (Basel). 2021 Jun 13; 13 (12) Epub 2021 June 13
    View PubMed
  7. Cox RE Jr, Mahipal A, Chakrabarti S. A Patient With Locally Advanced Mismatch-Repair-Deficient Pancreatic Ductal Adenocarcinoma Successfully Treated With Neoadjuvant Immunotherapy. Cureus. 2021 Apr 22; 13 (4):e14640
    View PubMed
  8. Aitcheson G, Mahipal A, John BV. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]? Expert Opin Investig Drugs. 2021 Apr; 30 (4):463-477 Epub 2021 Apr 11
    View PubMed
  9. Prasai K, Tella SH, Yadav S, Kommalapati A, Mara K, Mady M, Hassan MA, Wongjarupong N, Rodriguez-Payan N, Borad M, Patel T, Roberts LR, Mahipal A. Aspirin and Statin Use and the Risk of Gallbladder Cancer. Cancers (Basel). 2021 Mar 9; 13 (5) Epub 2021 Mar 09
    View PubMed
  10. Patel SR, Saliba AN, Steel S, Liewluck T, Mahipal A. Metastatic Colon Cancer Presenting With Immune-mediated Necrotizing Myopathy. Clin Colorectal Cancer. 2021 Mar; 20 (1):e71-e73 Epub 2020 Aug 29
    View PubMed
  11. Tella SH, Kommalapati A, Mahipal A. Systemic therapy for advanced hepatocellular carcinoma: targeted therapies. Chin Clin Oncol. 2021 Feb; 10 (1):10 Epub 2020 May 14
    View PubMed
  12. Antwi SO, Bamlet WR, Cawthon RM, Rabe KG, Druliner BR, Sicotte H, Jatoi A, Mahipal A, Boardman LA, Oberg AL, Petersen GM. Shorter Treatment-Naive Leukocyte Telomere Length is Associated with Poorer Overall Survival of Patients with Pancreatic Ductal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2021 Jan; 30 (1):210-216 Epub 2020 Nov 13
    View PubMed
  13. Breen WG, Jethwa KR, Yu NY, Spears GM, Harmsen WS, Miller RC, Ashman JB, Rule WG, Sio TT, Neben-Wittich MA, Haddock MG, Mahipal A, Truty MJ, Hallemeier CL, Merrell KW. Patient-Reported Quality of Life Before and After Chemoradiation for Intact Pancreas Cancer: A Prospective Registry Study. Pract Radiat Oncol. 2021 Jan-Feb; 11 (1):e63-e69 Epub 2020 July 23
    View PubMed
  14. Kowalchuk RO, Lester SC, Graham RP, Harmsen WS, Zhang L, Halfdanarson TR, Smoot RL, Gits HC, Ma WW, Owen D, Mahipal A, Miller RC, Wittich MAN, Cleary SP, McWilliams RR, Haddock MG, Hallemeier CL, Truty MJ, Merrell KW. Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9. Front Oncol. 2021; 11:651119 Epub 2021 May 11
    View PubMed
  15. Kim R, Tan E, Wang E, Mahipal A, Chen DT, Cao B, Masawi F, Machado C, Yu J, Kim DW. A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer. Oncologist. 2020 Dec; 25 (12):e1893-e1899 Epub 2020 Sept 14
    View PubMed
  16. Tella SH, Kommalapati A, Alberts SR, McWilliams R, Mahipal A. Collateral damage of COVID-19 pandemic on oncology clinical trials. Chin Clin Oncol 2020 Dec; 9 (6):80 Epub 2020 Nov 18
    View PubMed
  17. Jethwa KR, Sannapaneni S, Mullikin TC, Harmsen WS, Petersen MM, Antharam P, Laughlin B, Mahipal A, Halfdanarson TR, Merrell KW, Neben-Wittich M, Sio TT, Haddock MG, Hallemeier CL. Chemoradiotherapy for patients with locally advanced or unresectable extra-hepatic biliary cancer. J Gastrointest Oncol. 2020 Dec; 11 (6):1408-1420
    View PubMed
  18. Sonbol MB, Riaz IB, Naqvi SAA, Almquist DR, Mina S, Almasri J, Shah S, Almader-Douglas D, Uson Junior PLS, Mahipal A, Ma WW, Jin Z, Mody K, Starr J, Borad MJ, Ahn DH, Murad MH, Bekaii-Saab T. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis. JAMA Oncol. 2020 Dec 1; 6 (12):e204930 Epub 2020 Dec 10
    View PubMed
  19. Xie H, Liu J, Yin J, Ogden JR, Mahipal A, McWilliams RR, Truty MJ, Bekaii-Saab TS, Petersen GM, Jatoi A, Hubbard JM, Ma WW. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. Oncologist. 2020 Nov; 25 (11):e1681-e1690 Epub 2020 Aug 04
    View PubMed
  20. Mahipal A, Tella SH, Kommalapati A, Yu J, Kim R. Prevention and treatment of FGFR inhibitor-associated toxicities. Crit Rev Oncol Hematol. 2020 Nov; 155:103091 Epub 2020 Sept 01
    View PubMed
  21. Mady M, Prasai K, Tella SH, Yadav S, Hallemeier CL, Rakshit S, Roberts L, Borad M, Mahipal A. Neutrophil to lymphocyte ratio as a prognostic marker in metastatic gallbladder cancer. HPB (Oxford). 2020 Oct; 22 (10):1490-1495 Epub 2020 Feb 28
    View PubMed
  22. Chakrabarti S, Xie H, Urrutia R, Mahipal A. The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review. Cancers (Basel). 2020 Sep 29; 12 (10) Epub 2020 Sept 29
    View PubMed
  23. Chakrabarti S, Peterson CY, Sriram D, Mahipal A. Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions. World J Gastrointest Oncol. 2020 Aug 15; 12 (8):808-832
    View PubMed
  24. Xie H, Liu J, Ogden JR, Yin J, Jatoi A, Hubbard JM, McWilliams RR, Mahipal A, Petersen GM, Bekaii-Saab TS, Ma WW. Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Am J Clin Oncol. 2020 Aug; 43 (8):586-590
    View PubMed
  25. Chakrabarti S, Kamgar M, Mahipal A. Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm. Cancers (Basel). 2020 Jul 24; 12 (8) Epub 2020 July 24
    View PubMed
  26. Kim RD, Azad NS, Morse MA, Poplin E, Mahipal A, Tan B Jr, Mavroukakis SA, Fantini M, Tsang KY, Zaki A, Torrealba J, Arlen PM, Beg MS. Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer. Clin Cancer Res. 2020 Jul 15; 26 (14):3557-3564 Epub 2020 Apr 17
    View PubMed
  27. Abdallah MA, Wongjarupong N, Hassan MA, Taha W, Abdalla A, Bampoh S, Onyirioha K, Nelson M, Glubranson LA, Wiseman GA, Fleming CJ, Andrews JC, Mahipal A, Roberts LR. The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study. Expert Rev Gastroenterol Hepatol. 2020 Jul; 14 (7):619-629 Epub 2020 June 22
    View PubMed
  28. Kim RD, Chung V, Alese OB, El-Rayes BF, Li D, Al-Toubah TE, Schell MJ, Zhou JM, Mahipal A, Kim BH, Kim DW. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. JAMA Oncol. 2020 Jun 1; 6 (6):888-894
    View PubMed
  29. Kommalapati A, Tella SH, Yadav S, Goyal G, Hallemeier C, Durgin L, Jin Z, Mahipal A. Survival and prognostic factors in patients with rectal squamous cell carcinoma. Eur J Surg Oncol. 2020 Jun; 46 (6):1111-1117 Epub 2020 Mar 04
    View PubMed
  30. Chakrabarti S, Zemla TJ, Ahn DH, Ou FS, Fruth B, Borad MJ, Hartgers ML, Wessling J, Walkes RL, Alberts SR, McWilliams RR, Liu MC, Durgin LM, Bekaii-Saab TS, Mahipal A. Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma. Oncologist. 2020 May; 25 (5):380-e763 Epub 2019 Dec 11
    View PubMed
  31. Tella SH, Kommalapati A, Yadav S, Bergquist JR, Goyal G, Durgin L, Borad M, Cleary SP, Truty MJ, Mahipal A. Novel staging system using carbohydrate antigen (CA) 19-9 in extra-hepatic cholangiocarcinoma and its implications on overall survival. Eur J Surg Oncol. 2020 May; 46 (5):789-795 Epub 2020 Jan 11
    View PubMed
  32. Azmi AS, Khan HY, Muqbil I, Aboukameel A, Neggers JE, Daelemans D, Mahipal A, Dyson G, Kamgar M, Al-Hallak MN, Tesfaye A, Kim S, Shidham V, M Mohammad R, Philip PA. Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2020 Mar 15; 26 (6):1338-1348 Epub 2019 Dec 12
    View PubMed
  33. Yadav S, Tella SH, Kommalapati A, Mara K, Prasai K, Mady MH, Hassan M, Smoot RL, Cleary SP, Truty MJ, Roberts LR, Mahipal A. A Novel Clinically Based Staging System for Gallbladder Cancer. J Natl Compr Canc Netw. 2020 Feb; 18 (2):151-159
    View PubMed
  34. Tella SH, Kommalapati A, Borad MJ, Mahipal A. Second-line therapies in advanced biliary tract cancers. Lancet Oncol. 2020 Jan; 21 (1):e29-e41
    View PubMed
  35. Hyman DM, Tran B, Paz-Ares L, Machiels JP, Schellens JH, Bedard PL, Campone M, Cassier PH, Saratopoulos J, Vaishampayan U, Chugh R, Mahipal A, Lockhart AC, Sessa C, Zander T, Ng M, Curigliano G, Bendiske J, Chen X, Choudhury S, Graus-Porta D, Lewis N, Perez JM, Jose M. Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations. JCO Precision Oncology. 2019; 3.
  36. Tella SH, Kommalapati A, Yadav S, Bergquist JR, Truty MJ, Durgin L, Ma WW, Cleary SP, McWilliams RR, Mahipal A. Survival and prognostic factors in patients with pancreatic squamous cell carcinoma. Eur J Surg Oncol. 2019 Sep; 45 (9):1700-1705 Epub 2019 May 15
    View PubMed
  37. Huffman BM, Jin Z, Yadav S, Patel S, Nagorney DM, Truty MJ, McWilliams RR, Halfdanarson TR, Mahipal A. Novel Prognostic Factors in Resected Small Bowel Adenocarcinoma. Clin Colorectal Cancer. 2019 Sep; 18 (3):218-225 Epub 2019 May 15
    View PubMed
  38. Mahipal A, Tella SH, Kommalapati A, Anaya D, Kim R. FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma. Cancer Treat Rev. 2019 Aug; 78:1-7 Epub 2019 June 22
    View PubMed
  39. Yadav S, Xie H, Bin-Riaz I, Sharma P, Bin-Riaz I, Durani U, Goyal G, Borah B, Borad MJ, Smoot RL, Roberts LR, Go RS, McWilliams RR, Mahipal A. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis. Eur J Surg Oncol. 2019 Aug; 45 (8):1432-1438 Epub 2019 Mar 21
    View PubMed
  40. Mahipal A, Tella SH, Kommalapati A, Lim A, Kim R. Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel? Cancers (Basel). 2019 Jul 30; 11 (8) Epub 2019 July 30
    View PubMed
  41. Mahipal A, Ejadi S, Gnjatic S, Kim-Schulze S, Lu H, Ter Meulen JH, Kenney R, Odunsi K. First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1. Cancer Immunol Immunother. 2019 Jul; 68 (7):1211-1222 Epub 2019 May 08
    View PubMed
  42. Mahipal A, Tella SH, Kommalapati A, Goyal G, Soares H, Neuger A, Copolla D, Kim J, Kim R. Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. Invest New Drugs. 2019 Jun; 37 (3):473-481 Epub 2018 Oct 09
    View PubMed
  43. Chakrabarti S, Tella SH, Kommalapati A, Huffman BM, Yadav S, Riaz IB, Goyal G, Mody K, Borad M, Cleary S, Smoot RL, Mahipal A. Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. J Gastrointest Oncol. 2019 Jun; 10 (3):554-561
    View PubMed
  44. Chakrabarti S, Jin Z, Huffman BM, Yadav S, Graham RP, Lam-Himlin DM, Lightner AL, Hallemeier CL, Mahipal A. Local excision for patients with stage I anal canal squamous cell carcinoma can be curative. J Gastrointest Oncol. 2019 Apr; 10 (2):171-178
    View PubMed
  45. Sanhueza CT, Huffman BM, Jin Z, Hartgers ML, Smyrk TC, Westin G, McWilliams RR, Ma WW, Alberts SR, Mahipal A. Solid Pseudopapillary Neoplasms of the Pancreas: A Large American Cohort. Pancreas 2019 Apr; 48 (4):e21-e22
    View PubMed
  46. Mody K, Kasi PM, Yang JD, Surapaneni PK, Bekaii-Saab T, Ahn DH, Mahipal A, Sonbol MB, Starr JS, Roberts A, Nagy R, Lanman R, Borad MJ. Circulating tumor dna profiling of advanced biliary tract cancers JCO Precision Oncology. 2019 Mar 18; 3
  47. Kommalapati A, Tella SH, Goyal G, Borad M, Alberts SR, Roberts L, Hubbard JM, Durgin L, Cleary S, Mahipal A. Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma. HPB (Oxford). 2019 Mar; 21 (3):379-386 Epub 2018 Sept 25
    View PubMed
  48. Wolin E, Mita A, Mahipal A, Meyer T, Bendell J, Nemunaitis J, Munster PN, Paz-Ares L, Filvaroff EH, Li S, Hege K, de Haan H, Mita M. A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. PLoS One. 2019; 14 (9):e0221994 Epub 2019 Sept 17
    View PubMed
  49. Tella SH, Mahipal A, Kommalapati A, Jin Z. Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date. Onco Targets Ther. 2019; 12:10335-10342 Epub 2019 Nov 28
    View PubMed
  50. Munster P, Mita M, Mahipal A, Nemunaitis J, Massard C, Mikkelsen T, Cruz C, Paz-Ares L, Hidalgo M, Rathkopf D, Blumenschein G Jr, Smith DC, Eichhorst B, Cloughesy T, Filvaroff EH, Li S, Raymon H, de Haan H, Hege K, Bendell JC. First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. Cancer Manag Res. 2019; 11:10463-10476 Epub 2019 Dec 13
    View PubMed
  51. Mahipal A, Kommalapati A, Mehta R, Kim RD. Molecular-Targeted Therapies in Hepatocellular Carcinoma Hoshida Y editor.Hepatocellular Carcinoma: Translational Precision Medicine Approaches Cham (CH) Humana Press 2019225-238
    View PubMed
  52. Yadav S, Xie H, Riaz IB, Sharma P, Mahipal A, McWilliams R. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis. Ann Oncol. 2018 Oct; 29 Suppl 8:viii260-viii261
    View PubMed
  53. Huffman BM, Westin G, Alsidawi S, Alberts SR, Nagorney DM, Halfdanarson TR, Mahipal A. Survival and Prognostic Factors in Patients With Solid Pseudopapillary Neoplasms of the Pancreas. Pancreas. 2018 Sep; 47 (8):1003-1007
    View PubMed
  54. DeLeon TT, Zhou Y, Nagalo BM, Yokoda RT, Ahn DH, Ramanathan RK, Salomao MA, Aqel BA, Mahipal A, Bekaii-Saab TS, Borad MJ. Novel immunotherapy strategies for hepatobiliary cancers. Immunotherapy. 2018 Sep; 10 (12):1077-1091
    View PubMed
  55. Mahipal A, Kommalapati A, Tella SH, Lim A, Kim R. Novel targeted treatment options for advanced cholangiocarcinoma. Expert Opin Investig Drugs. 2018 Sep; 27 (9):709-720 Epub 2018 Aug 30
    View PubMed
  56. Jin Z, Hartgers ML, Sanhueza CT, Shubert CR, Alberts SR, Truty MJ, Muppa P, Nagorney DM, Smyrk TC, Hassan M, Mahipal A. Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience. Eur J Surg Oncol. 2018 May; 44 (5):677-683 Epub 2018 Feb 16
    View PubMed
  57. Kommalapati A, Tella SH, Goyal G, Ma WW, Mahipal A. Contemporary Management of Localized Resectable Pancreatic Cancer. Cancers (Basel). 2018 Jan 20; 10 (1)
    View PubMed
  58. Chaker M, Minden A, Chen S, Weiss RH, Chini EN, Mahipal A, Azmi AS. Rho GTPase effectors and NAD metabolism in cancer immune suppression. Expert Opin Ther Targets. 2018 Jan; 22 (1):9-17 Epub 2017 Dec 10
    View PubMed
  59. Huffman B, Westin G, Mahipal A. Survival analysis of patients with solid pseudopapillary tumors of the pancreas in a multicenter retrospective cohort. Ann Oncol. 2017 Jun; 28 Suppl 3:iii137
    View PubMed
  60. Kim DW, Byer J, Kothari N, Mahipal A, Chang YD, Kim RD. EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience. Oncology. 2017; 92: (4)190-196.
    View PubMed
  61. Thompson SM, Zendejas-Mummert B, Hartgers ML, Venkatesh SK, Smyrk TC, Mahipal A, Smoot RL. Malignant transformation of biliary adenofibroma: a rare biliary cystic tumor. J Gastrointest Oncol. 2016 Dec; 7 (6):E107-E112
    View PubMed
  62. Mahipal A, Grothey A. Role of Biologics in First-Line Treatment of Colorectal Cancer. J Oncol Pract. 2016 Dec; 12 (12):1219-1228
    View PubMed
  63. Chow LQ, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol. 2016 Sep 19;
    View PubMed
  64. Mahipal A, Malafa M. Importins and exportins as therapeutic targets in cancer. Pharmacol Ther. 2016 Aug; 164:135-43 Epub 2016 Apr 23
    View PubMed
  65. Mahipal A, Klapman J, Vignesh S, Yang CS, Neuger A, Chen DT, Malafa MP. Pharmacokinetics and safety of vitamin E delta-tocotrienol after single and multiple doses in healthy subjects with measurement of vitamin E metabolites. Cancer Chemother Pharmacol. 2016 Jul; 78: (1)157-65.
    View PubMed
  66. Abdul Razak AR, Mau-Soerensen M, Gabrail NY, Gerecitano JF, Shields AF, Unger TJ, Saint-Martin JR, Carlson R, Landesman Y, McCauley D, Rashal T, Lassen U, Kim R, Stayner LA, Mirza MR, Kauffman M, Shacham S, Mahipal A. First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors. J Clin Oncol. 2016 Feb 29;
    View PubMed
  67. Mahipal A, Shibata D, Siegel E, Almhanna K, Springett G, Fulp W, Williams-Elson I, Kim R. Phase I Trial of Combination of FOLFIRI and Pasireotide, a Somatostatin Analogue, in Advanced Gastrointestinal Malignancies. Investigational New Drugs.2016;33:(5)1093-9.
  68. Sajjad M, Batra S, Hoffe S, Kim R, Springett G, Mahipal A. Use of Radiation Therapy in Locally Advanced Pancreatic Cancer Improves Survival: A SEER Database Analysis. Am J Clin Oncol. 2016 Jan 19;
    View PubMed
  69. Ambe CM, Mahipal A, Fulp J, Chen L, Malafa MP. Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the Literature. PLoS One. 2016; 11: (3)e0151632.
    View PubMed
  70. Kim R, Prithviraj G, Kothari N, Springett G, Malafa M, Hodul P, Kim J, Yue B, Morse B, Mahipal A. PET/CT Fusion Scan Prevents Futile Laparotomy in Early Stage Pancreatic Cancer. Clin Nucl Med. 2015 Nov; 40: (11)e501-5.
    View PubMed
  71. Denson A, Burke N, Wapinsky G, Bertels B, Juan TH, Lee J, Springett GM, Strosberg JR, Kim RD, Sullivan DM, Mahipal A. Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials. Am J Clin Oncol. 2015 Oct 29;
    View PubMed
  72. Mahipal A, Frakes J, Hoffe S, Kim R. Management of borderline resectable pancreatic cancer. World J Gastrointest Oncol. 2015 Oct 15; 7: (10)241-9.
    View PubMed
  73. Mahipal A, Choi M, Kim R. Second-Line Treatment of Advanced Gastric Cancer: Where Do We Stand? J Natl Compr Canc Netw. 2015 Oct; 13: (10)1281-91; quiz 1292.
    View PubMed
  74. Ambe C, Fulp W, Springett G, Hoffe S, Mahipal A. A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer. J Gastrointest Cancer. 2015 Sep; 46: (3)284-90.
    View PubMed
  75. Suleiman Y, Mahipal A, Shibata D, Siegel EM, Jump H, Fulp WJ, Springett GM, Kim R. Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2015 Sep; 76: (3)481-7.
    View PubMed
  76. Kazim S, Malafa MP, Coppola D, Husain K, Zibadi S, Kashyap T, Crochiere M, Landesman Y, Rashal T, Sullivan DM, Mahipal A. Selective nuclear export inhibitor KPT-330 enhances the antitumor activity of gemcitabine in human pancreatic cancer. Molecular Cancer Therapeutics.2015;14:(7)1570-81.
  77. Papadopoulos KP, Isaacs R, Bilic S, Kentsch K, Huet HA, Hofmann M, Rasco D, Kundamal N, Tang Z, Cooksey J, Mahipal A. Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody(R) targeting the DR5 receptor. Cancer Chemother Pharmacol. 2015 May; 75: (5)887-95.
    View PubMed
  78. Saneeymehri SS, Markey KR, Mahipal A. Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review. J Oncol Pharm Pract. 2015 Apr 6;
    View PubMed
  79. Mahipal A, Denson AC, Djulbegovic B, Lush R, Kumar A, Juan TH, Schell MJ, Sullivan DM. Effect of Age on Clinical Outcomes in Phase 1 Trial Participants. Cancer Control.2015;22:(2)235-41.
  80. Mahipal A, Nguyen D. Risks and benefits of phase 1 clinical trial participation. Cancer Control. 2014 Jul; 21: (3)193-9.
    View PubMed
  81. Mahipal A. Clinical trials and drug development. Cancer Control. 2014 Jul; 21: (3)188-9.
    View PubMed
  82. Denson AC, Mahipal A. Participation of the elderly population in clinical trials: barriers and solutions. Cancer Control. 2014 Jul; 21: (3)209-14.
    View PubMed
  83. Riaz W, Burke N, Mahipal A. Selinexor. Exportin-1 (XPO1) inhibitor, Oncolytic. Drugs of the Future.2014;39:(10)685.
  84. Kim R, Byer J, Fulp WJ, Mahipal A, Dinwoodie W, Shibata D. Carboplatin and paclitaxel treatment is effective in advanced anal cancer. Oncology. 2014; 87: (2)125-32.
    View PubMed
  85. Mahipal A, Kothari N, Gupta S. Epidermal growth factor receptor inhibitors: coming of age. Cancer Control. 2014 Jan; 21: (1)74-9.
    View PubMed
  86. Ashraf N, Mahipal A, Kim R. Viral Vector Vaccines To Treat Colorectal Cancer. Curr Colorectal Cancer Rep.2013;9:398-405.
  87. Kim R, Mahipal A, Choi M, Saif MW. Biomarkers for pancreatic cancer: is it ready for primetime? JOP. 2013 Jul; 14: (4)309-11.
    View PubMed
  88. Gupta S, Mahipal A. Role of systemic chemotherapy in urothelial urinary bladder cancer. Cancer Control. 2013 Jul; 20: (3)200-10.
    View PubMed
  89. Mahipal A, Mitchell E. Gemcitabine, Oxaliplatin and Bevacizumab in patients with biliary tract cancers. Journal of Solid Tumors.2013;3:(3)29.
  90. Mahipal A, Tijani L, Chan K, Laudadio M, Mastrangelo MJ, Sato T. A pilot study of sunitinib malate in patients with metastatic uveal melanoma. Melanoma Res. 2012 Dec; 22: (6)440-6.
    View PubMed
  91. Mahipal A, Mcdonald MJ, Witkiewicz A, Carr BI. Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma. Med Oncol. 2012 Mar; 29: (1)134-9.
    View PubMed
  92. Sbenghe MM, Besa E, Mahipal A, Dulau Florea A, Bray P, Caro J. HHV-8-associated multicentric Castleman's disease in HIV-negative patient: a novel therapy for an orphan disease. Oncologist. 2012; 17: (1)145-6; author reply 147-8.
    View PubMed
  93. Mahipal A, Terai M, Berd D, Chervoneva I, Patel K, Mastrangelo MJ, Sato T. Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. Cancer Immunol Immunother. 2011 Jul; 60: (7)1039-45.
    View PubMed
  94. Mahipal A, Gupta S. Small-cell carcinoma of the gallbladder: report of a case and literature review. Gastrointest Cancer Res. 2011 Jul; 4: (4)135-6.
    View PubMed
  95. Mahipal A, Weiss M. The addition of rituximab to fludarabine and cyclophosphamide improves progression-free survival in patients with previously treated chronic lymphocytic leukemia. Curr Oncol Rep. 2010 Nov; 12: (6)352-4.
    View PubMed
  96. Gupta S, Mahipal A. A case of acquired hemophilia associated with bullous pemphigoid. Am J Hematol. 2007 Jun; 82: (6)502.
    View PubMed
  97. Mahipal A, Bilgrami S. Acquired hemophilia in chronic lymphocytic leukemia. Leuk Lymphoma. 2007 May; 48: (5)1026-8.
    View PubMed
  98. Gupta S, Mahipal A. Fatal pulmonary toxicity after a single dose of cyclophosphamide. Pharmacotherapy. 2007 Apr; 27: (4)616-8.
    View PubMed
  99. Mahipal A, Anderson KE, Limburg PJ, Folsom AR. Nonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev. 2006 Oct; 15: (10)1785-90.
    View PubMed
  100. Mahipal A, Anderson KE, Limburg PJ, Folsom AR. Nonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev.2006;15:(10)1785-90.
  101. Swenson KK, Mahipal A, Nissen MJ, Tuttle TM, Heaton K, Lally RM, Spomer A, Lee MW. Axillary disease recurrence after sentinel lymph node dissection for breast carcinoma. Cancer. 2005 Nov 1; 104: (9)1834-9.
    View PubMed